AL 335/odalasvir/simeprevir - Janssen/Medivir

Drug Profile

AL 335/odalasvir/simeprevir - Janssen/Medivir

Alternative Names: 3DAA FDC - Medivir; AL-335/odalasvir/simeprevir - Janssen/Medivir; JNJ-4178; odalasvir/simeprevir/AL-335 - Janssen/Medivir; simeprevir/AL-335/odalasvir - Janssen/Medivir

Latest Information Update: 13 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Medivir AB
  • Developer Janssen; Medivir AB
  • Class 3-ring heterocyclic compounds; Antivirals; Benzimidazoles; Cyclopropanes; Indoles; Pyrimidine nucleotides; Quinolines; Small molecules; Sulfonamides; Thiazoles; Uracil nucleotides
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 01 Nov 2017 Janssen Research & Development completes the OMEGA-1 phase IIb trial for Hepatitis C in Belgium, Canada, Germany, Poland, Singapore and Spain (NCT02765490)
  • 23 Oct 2017 Efficacy data from the phase IIb OMEGA-1 trial in Hepatitis C, which met its primary endpoint, presented at the The Liver Meeting 2017, 68th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2017)
  • 20 Oct 2017 Safety data from the phase IIb OMEGA-1 trial in Hepatitis C presented at the 68th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top